News
TAPISTRY (BO41932): Clinical trial for patients...
TAPISTRY (BO41932) is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified...
TAPISTRY (BO41932): Clinical trial for patients...
TAPISTRY (BO41932) is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified...
New collaborations set to attack RET driven non...
Exciting news from RETpositive and our partners at The Happy Lungs Project! This is a new initiative bringing together and funding several top institutions all across the US to work...
New collaborations set to attack RET driven non...
Exciting news from RETpositive and our partners at The Happy Lungs Project! This is a new initiative bringing together and funding several top institutions all across the US to work...
Survey Study: Help researchers understand the t...
Do you want to shape the future of lung cancer? We’re partnering with LUNGevity Foundation to learn about access to treatments and biomarker testing. By sharing your experience, you can...
Survey Study: Help researchers understand the t...
Do you want to shape the future of lung cancer? We’re partnering with LUNGevity Foundation to learn about access to treatments and biomarker testing. By sharing your experience, you can...
TROPION-LUNG01 trial showing good duration of r...
OncLive is reporting the preliminary research in the clinical trial for Trop2-ADC is looking promising. While not RET specific, for those that advance or do not respond to RET specific...
TROPION-LUNG01 trial showing good duration of r...
OncLive is reporting the preliminary research in the clinical trial for Trop2-ADC is looking promising. While not RET specific, for those that advance or do not respond to RET specific...
Free patient access to health and medical resea...
Elsevier, a medical research publisher, provides free access to medical and health care papers for patients and caregivers. To request access, you must email patientaccess@elsevier.com. Elsevier indicates they will aim...
Free patient access to health and medical resea...
Elsevier, a medical research publisher, provides free access to medical and health care papers for patients and caregivers. To request access, you must email patientaccess@elsevier.com. Elsevier indicates they will aim...
Just announced! Research funding award for up t...
RETpositive is thrilled to announce the call for applications to award both a $200,000 grant as well as a one million dollar funding award for medical research specifically looking at...
Just announced! Research funding award for up t...
RETpositive is thrilled to announce the call for applications to award both a $200,000 grant as well as a one million dollar funding award for medical research specifically looking at...